文献速递肝病消化道肿瘤与早癌

绝经后女性循环性激素水平与肝癌风险的关联

Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women.
PubMed 文献 · Hepatology · 2020-01-01

该研究基于五项前瞻性队列,纳入191例绝经后女性肝癌病例(肝细胞癌83例、肝内胆管癌56例)和426名对照,检测基线血清/血浆中七种性激素和性激素结合球蛋白水平。结果显示,4-雄烯二酮浓度每翻倍与肝癌风险降低50%相关,而性激素结合球蛋白每翻倍与风险增加31%相关;雌二醇每翻倍与肝内胆管癌风险增加40%相关,但与肝细胞癌无关。

要点

  • 4-雄烯二酮浓度翻倍与绝经后女性肝癌风险降低50%相关。
  • 性激素结合球蛋白浓度翻倍与肝癌风险增加31%相关。
  • 雌二醇浓度翻倍与肝内胆管癌风险增加40%相关,与肝细胞癌无关。

核心结论

  • 较高4-雄烯二酮水平可能与绝经后女性肝癌风险降低相关。
  • 较高性激素结合球蛋白水平可能与肝癌风险升高相关。
  • 该研究不支持较高雌激素水平降低肝癌风险的假说。
  • 雌二醇水平可能与肝内胆管癌风险升高相关。

研究设计与样本

  • 研究利用五项前瞻性队列资源,纳入191例绝经后女性肝癌病例(肝细胞癌83例、肝内胆管癌56例)和426名对照。
  • 采用气相色谱-串联质谱法检测七种性激素,竞争性电化学发光免疫分析法检测性激素结合球蛋白。
  • 对照按性别、队列、年龄、种族/民族和采血日期匹配。
  • 使用多变量调整的条件logistic回归计算每单位log2激素值增加(约循环浓度翻倍)的比值比和95%置信区间。

主要发现

  • 4-雄烯二酮浓度每翻倍与肝癌风险降低50%相关(OR=0.50;95%CI=0.30-0.82)。
  • 性激素结合球蛋白浓度每翻倍与肝癌风险增加31%相关(OR=1.31;95%CI=1.05-1.63)。
  • 雌二醇浓度每翻倍与肝内胆管癌风险增加40%相关(OR=1.40;95%CI=1.05-1.89)。
  • 雌二醇浓度每翻倍与肝细胞癌风险无显著关联(OR=1.12;95%CI=0.81-1.54)。

临床怎么用

  • 在绝经后女性中,检测循环4-雄烯二酮和性激素结合球蛋白水平可能有助于肝癌风险分层。
  • 雌二醇水平升高可能提示肝内胆管癌风险增加,需结合组织学类型评估。
  • 不应基于本研究结果推荐雌激素用于降低肝癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In almost all countries, incidence rates of liver cancer (LC) are 100%-200% higher in males than in females. However, this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% of LC cases. Intrahepatic cholangiocarcinoma (ICC) accounts for 12% of cases and has rates only 30% higher in males. Hormones are hypothesized to underlie observed sex differences. We investigated whether prediagnostic circulating hormone and sex hormone binding globulin (SHBG) levels were associated with LC risk, overall and by histology, by leveraging resources from five prospective cohorts. APPROACH AND RESULTS: Seven sex steroid hormones and SHBG were quantitated using gas chromatography/tandem mass spectrometry and competitive electrochemiluminescence immunoassay, respectively, from baseline serum/plasma samples of 191 postmenopausal female LC cases (HCC, n = 83; ICC, n = 56) and 426 controls, matched on sex, cohort, age, race/ethnicity, and blood collection date. Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between a one-unit increase in log2 hormone value (approximate doubling of circulating concentration) and LC were calculated using multivariable-adjusted conditional logistic regression. A doubling in the concentration of 4-androstenedione (4-dione) was associated with a 50% decreased LC risk (OR = 0.50; 95% CI = 0.30-0.82), whereas SHBG was associated with a 31% increased risk (OR = 1.31; 95% CI = 1.05-1.63). Examining histology, a doubling of estradiol was associated with a 40% increased risk of ICC (OR = 1.40; 95% CI = 1.05-1.89), but not HCC (OR = 1.12; 95% CI = 0.81-1.54). CONCLUSIONS: This study provides evidence that higher levels of 4-dione may be associated with lower, and SHBG with higher, LC risk in women. However, this study does not support the hypothesis that higher estrogen levels decrease LC risk. Indeed, estradiol may be associated with an increased ICC risk.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Petrick JL, Florio AA, Zhang X, et al. Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women. Hepatology. 2020. PMID: 31808181. doi:10.1002/hep.31057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。